Skip to main content
. 2021 Feb 8;6(3):e138385. doi: 10.1172/jci.insight.138385

Figure 7. The synthetic PDE4 inhibitor rolipram suppresses APS-mediated NETosis and venous thrombosis.

Figure 7

Human neutrophils were stimulated with APS IgG for 3 hours. Some samples were additionally treated with the PDE4 inhibitor rolipram. NETosis was quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO) (A). MPO-DNA complexes were assessed for control IgG- or APS IgG-treated mice in the presence or absence of rolipram (B). Thrombus formation was assessed at 24 hours. Thrombus length (C) and thrombus weight (D) were measured; **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA corrected with Dunnett’s test.